Corcept Therapeutics CORT Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProfitLoss.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's net income?
- Corcept Therapeutics (CORT) reported net income of -$31.76M in Q1 2026.
- How has Corcept Therapeutics's net income changed year-over-year?
- Corcept Therapeutics's net income decreased by 254.6% year-over-year, from $20.55M to -$31.76M.
- What is the long-term trend for Corcept Therapeutics's net income?
- Over 4 years (2021 to 2025), Corcept Therapeutics's net income has grown at a -3.0% compound annual growth rate (CAGR), from $112.51M to $99.65M.
- What does net income mean?
- The total profit a company earned during a specific period.
- How do you interpret net income?
- An increase indicates higher profitability, while a decrease suggests declining margins or rising costs.
- How does net income compare across companies?
- Standard across all public companies; peers in biotech typically show high volatility based on R&D cycles.